Multiple CAR-T Cell Therapy Targeting AML
NCT04010877
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL:
CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells
Sponsor
Shenzhen Geno-Immune Medical Institute